Skip to main content
2025 CRT Conference Main banner

CRT 2025

Spotlight

Challenges in Clinical Trial Design

Panel Discussion

Monday, March 10, 2025
12:25 PM - 12:35 PM ET

    Panel Moderator(s)

  • Donald E. Cutlip, MD, FACC

    Vice Chair, Department of Medicine
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts, United States

    No relationships to disclose

    • Panel Discussant(s)

  • Jodi J. Akin, MS

    Chairwoman, BOD
    CoreMedic
    Alamo, California, United States

    Disclosure(s): No financial relationships to disclose

  • Andrew D. Althouse, PhD

    Senior Principal Statistician
    Medtronic

    No relationships to disclose

  • C. Michael Gibson, MD

    Professor of Medicine
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts, United States

    No relationships to disclose

  • Biljana Parapid, MD, PhD

    Assistant Professor, Department of Medicine - Cardiology
    Belgrade University School of Medicine
    Belgrade, Serbia

    No relationships to disclose

  • Shelby D. Reed, PhD

    Professor
    Duke Clinical Research Institute
    Durham, North Carolina, United States

    Disclosure(s): No financial relationships to disclose

  • Samantha Stone Barrett, MPH

    Director of Strategic Operations for MedTech and Real-World Services
    IQVIA
    Stamford, Connecticut, United States

    No relationships to disclose

    • Panel Moderator(s)

  • Jan Tijssen, PhD

    Emeritus Professor of Clinical Biostatistics
    Amsterdam University Medical Centers - University of Amsterdam
    Naarden, Noord-Holland, Netherlands

    No relationships to disclose

    • Panel Discussant(s)

  • William S. Weintraub, MD

    Cardiologist
    MedStar Washington Hospital Center
    Washington, District of Columbia, United States

    Disclosure(s): No financial relationships to disclose

  • Roseann M. White, MA

    Principal Statistical Consultant
    Your 3rd Opinion
    Chapel Hill, North Carolina, United States

    Disclosure(s): Abbott Labs: Pension (Ongoing); Abiomed Inc: Consultant (Ongoing); Edward Lifesciences: Employee (Terminated, April 5, 2024); Natera: Stock-publicly held company (excluding mutual/index funds) (Ongoing); SciTech: Consultant (Ongoing)

Disclosure(s):
Donald E. Cutlip, MD, FACC: Boston Scientifiic: Consultant (Terminated, December 12, 2024); MedAlliance: Grant/Research Support (Ongoing)
Jodi J. Akin, MS: No financial relationships to disclose
Andrew D. Althouse, PhD: Medtronic: Employee (Ongoing)
C. Michael Gibson, MD: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing)
Biljana Parapid, MD, PhD: No financial relationships to disclose
Shelby D. Reed, PhD: No financial relationships to disclose
Samantha Stone Barrett, MPH: Abbott Vascular, Medtronic, Boston Scientific: Stock-privately held company (Ongoing); Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk: Employee (Ongoing)
Jan Tijssen, PhD: No financial relationships to disclose
William S. Weintraub, MD: No financial relationships to disclose
Roseann M. White, MA: Abbott Labs: Pension (Ongoing); Abiomed Inc: Consultant (Ongoing); Edward Lifesciences: Employee (Terminated, April 5, 2024); Natera: Stock-publicly held company (excluding mutual/index funds) (Ongoing); SciTech: Consultant (Ongoing)